Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Aramchol meglumine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galmed's Oral Aramchol Meglumine Boosts Bioavailability 500%
    Galmed's Oral Aramchol Meglumine Boosts Bioavailability 500%

    14 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-results-from-first-in-man-pharmacokinetics-study-of-oral-formulation-of-aramchol-meglumine-am-400mg-am-increases-bioavailability-by-500-in-comparison-to-aramchol-free-acid-aa-300mg-302772195.html

    PR NEWSWIRE
    14 May 2026
    Share Share
    Galmed Reports Significant AM-001 Study Results For Aramchol
    Galmed Reports Significant AM-001 Study Results For Aramchol

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-meaningful-top-line-results-from-am-001-study-of-aramchol-meglumine-302618567.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    galmed identifies biomarker for aramchol, expanding beyond NASH
    galmed identifies biomarker for aramchol, expanding beyond NASH

    27 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-identifies-proprietary-biomarker-signature-for-aramchol-unlocking-multi-billion-dollar-expansion-potential-beyond-nash-302465691.html

    PR NEWSWIRE
    27 May 2025
    Share Share
    Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models
    Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models

    13 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-psc-models-302453710.html

    PR NEWSWIRE
    13 May 2025
    Share Share
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-first-time-results-in-oncology-studies-aramchol-significantly-enhances-bayers-regorafenib-effect-in-gi-cancer-models-302447161.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer
    Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer

    17 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-launches-vcu-collaboration-to-tackle-drug-resistance-in-gi-cancers-302431484.html

    PR NEWSWIRE
    17 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.